FY2024 EPS Estimates for Longeveron Increased by Analyst

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Longeveron in a research note issued to investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($2.83) for the year, up from their previous estimate of ($3.32). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Longeveron’s Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.46) EPS.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.19. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. The business had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.34 million. During the same period in the prior year, the company posted ($2.80) earnings per share.

Separately, Maxim Group reduced their price target on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th.

Longeveron Trading Up 2.0 %

Shares of LGVN opened at $2.00 on Wednesday. Longeveron has a 12 month low of $0.77 and a 12 month high of $23.90. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $2.13. The stock has a market capitalization of $29.68 million, a PE ratio of -0.32 and a beta of 0.36.

Institutional Investors Weigh In On Longeveron

A number of large investors have recently bought and sold shares of LGVN. Geode Capital Management LLC raised its position in shares of Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares in the last quarter. State Street Corp acquired a new position in Longeveron during the third quarter valued at approximately $29,000. Finally, Renaissance Technologies LLC bought a new stake in Longeveron during the second quarter worth $236,000. 10.01% of the stock is currently owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.